THE PROGNOSTIC-SIGNIFICANCE OF CA-125 HALF-LIFE IN PATIENTS WITH OVARIAN-CANCER WHO HAVE RECEIVED PRIMARY CHEMOTHERAPY AFTER SURGICAL CYTOREDUCTION

被引：59

作者：

HUNTER, VJ

DALY, L

HELMS, M

SOPER, JT

BERCHUCK, A

CLARKEPEARSON, DL

BAST, RC

机构：

[1] DUKE UNIV,MED CTR,DEPT HORT SCI & LANDSCAPE ARCHITECTURE,BOX 3843,DURHAM,NC 27710

[2] DUKE UNIV,MED CTR,DEPT COMMUNITY & FAMILY MED,DURHAM,NC 27710

[3] DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710

[4] DUKE UNIV,MED CTR,DEPT MICROBIOL IMMUNOL,DURHAM,NC 27710

[5] DUKE UNIV,MED CTR,DUKE COMPREHENS CANC CTR,DURHAM,NC 27710

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 1990年 / 163卷 / 04期

关键词：

CA; 125; half-life; ovarian cancer; prognosis;

D O I：

10.1016/0002-9378(90)90680-6

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of <20 days was associated with prolonged overall survival (p < 0.015). In those patients who eventually were found to be disease-free at surgical surveillance procedures, normalization of serum CA 125 levels to <35 U/ml within 65 days of primary operation also suggested an improved survival (p < 0.059). © 1990.

引用

页码：1164 / 1167

页数：4

共 9 条

[1] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].